Aims: The aims of this study are (i) to develop a population pharmacokinetic model of enzyme activity in Gaucher-type 1 (GD1) patients after intravenous administration of enzyme replacement therapy (ERT), and (ii) to establish an exposure-efficacy relationship for bone marrow infiltration to propose dose adjustments according to patient covariate values.
Methods: A prospective follow-up, semi-experimental multi-centre study was conducted in four hospitals to evaluate the pharmacokinetics, efficacy and safety of ERT in GD1 patients. Twenty-five individuals with 266 glucocerebrosidase (GCase) observations in plasma and leukocytes and 14 individuals with 68 Spanish magnetic resonance imaging (S-MRI) observations were enrolled.
Results: A two concatenated compartment model with zero-order endogenous production and first-order distribution (CL = 3.85 × 10 L/d) and elimination (CL = 1.25 L/d) allowed GCase observations in plasma and leukocytes to be described, respectively. An exponential time dependency (k = 6.14 × 10 d ) effect on CL was incorporated. The final exposure-efficacy model was a longitudinal logistic regression model with a first-order Markov element. An E function (EC = 15.73 U/L and E = 2.33) linked steady-state concentrations of GCase in leukocytes to the probability of transition across the different S-MRI stages.
Conclusion: A population pharmacokinetic model successfully characterized the leukocyte activity-time profiles of GCase following intravenous administration of ERT in GD1 patients together with an exposure-efficacy relationship in bone marrow using Markovian elements. The information obtained from this study could be of high clinical relevance in individualization of ERT in GD1 patients, as this could lead to anticipative decision-making regarding clinical response in bone and optimal dosing strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcp.15198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The lysosomal storage diseases chronic visceral acid sphingomyelinase deficiency (ASMD) and Gaucher disease type 1 (GD1) are both macrophage storage disorders with overlapping clinical manifestations. We compared cross-sectional data on visceral, hematological, and biochemical manifestations of untreated adult patients with chronic visceral ASMD ( = 19) and GD1 ( = 85). Spleen volume, liver volume, and bone marrow fat fraction did not significantly differ between the two disease groups ( >0.
View Article and Find Full Text PDFNon-neuronopathic Gaucher disease (Type I) in an elderly female: a case report.
Ann Med Surg (Lond)
November 2024
Department of General and Gastrointestinal Surgery, Nepal Mediciti, Lalitpur, Nepal.
Introduction And Importance: Gaucher disease is a rare autosomal recessive lysosomal storage disorder marked by a substantial reduction in beta-glucocerebrosidase activity. Historically, supportive treatments such as splenectomy and orthopedic interventions were employed, whereas recent advances have led to the approval of Enzyme Replacement Therapy (ERT) and Substrate Reduction Therapy (SRT) as therapeutic options.
Case Presentation: The authors present the case of a 61-year-old female with chronic abdominal pain, abdominal fullness, pancytopenia, and hepatosplenomegaly, all indicative of Gaucher's disease, later confirmed by histopathological examination.
Transition of patients with Gaucher disease type 1 from pediatric to adult care: results from two international surveys of patients and health care professionals.
Front Pediatr
August 2024
International Gaucher Alliance (IGA), London, United Kingdom.
Introduction: Gaucher disease (GD) is a rare, autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme glucocerebrosidase. The most common subtype in Europe and the USA, type 1 (GD1), is characterized by fatigue, cytopenia, splenomegaly, hepatomegaly, bone disease, and rarely pulmonary disease. Increased life expectancy brought about by improved treatments has led to new challenges for adolescents and their transition to adult care.
View Article and Find Full Text PDFMachine Learning-Driven Biomarker Discovery for Skeletal Complications in Type 1 Gaucher Disease Patients.
Int J Mol Sci
August 2024
Takeda Development Center Americas Inc., Cambridge, MA 02142, USA.
Type 1 Gaucher disease (GD1) is a rare, autosomal recessive disorder caused by glucocerebrosidase deficiency. Skeletal manifestations represent one of the most debilitating and potentially irreversible complications of GD1. Although imaging studies are the gold standard, early diagnostic/prognostic tools, such as molecular biomarkers, are needed for the rapid management of skeletal complications.
View Article and Find Full Text PDFThe natural history of Gaucher disease type 1 in 31 patients over a median of 15 years: a retrospective study.
Intern Med J
October 2024
Mark Freedman and Judy Jacobs Program for Gaucher Disease, Mount Sinai Hospital, Toronto, Ontario, Canada.
Article Synopsis
- The study focuses on the natural history of untreated type 1 Gaucher disease (GD1) in 31 patients, revealing uncertainty about the need for treatment, especially in mildly symptomatic cases.
- It’s a retrospective analysis that tracked clinical parameters like blood tests, organ sizes, and bone health over a median period of 15 years, showing most parameters remained stable.
- The results suggest that many patients can be monitored long-term without significant disease progression or the need for treatment, highlighting the importance of specialist care for managing GD1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!